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Background: Recurrent episodes of venous thrombosis have been closely correlated with JAK2 V617F mutation.
Upto date, JAK2 gene mutation has not been defined as a prothrombic risk factor in renal transplant recipients.
Herein; we present a case of portosplenic vein thrombosis in a primary renal transplant recipient with JAK2 V617F
mutation who had no history of prior venous thromboembolism or thrombophilia.
Case presentation: A 59 year old female caucasian patient with primary kidney transplant admitted with vague
abdominal pain at left upper quadrant. Abdominal doppler ultrasound and magnetic resonance imaging
angiography demonstrated splanchnic vein thrombosis (SVT). The final diagnosis was SVT due to MPD (essential
thrombocytosis, ET) with JAK2 V617F mutation. After 3 months of treatment with warfarin (≥5 mg/day, to keep
target INR values of 1.9-2.5), control MRI angiography and doppler USG demonstrated partial (>%50) resolution of
thrombosis with recanalization of hepatopedal venous flow. The patient is still on the same treatment protocol
without any complication.
Conclusion: JAK2 V617F mutation analysis should be a routine procedure in the diagnosis and treatment of kidney
transplant patients with thrombosis in uncommon sites.
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Renal transplantationBackground
Kidney transplantation for the management of end-stage
renal disease (ESRD) is still the best approach that
provides near-normal renal function, excellent survival
outcomes and improved quality of life with lowest
healthcare costs [1]. This picture is occasionally over-
shadowed by posttransplant thromboembolic events
which negatively influence graft and patient survival.
A hypercoagulable state early after transplanation
may cause deep venous thrombosis and induces devas-
tating complications like pulmonary embolism and
death [2-4].
The description of Janus Kinase 2 (JAK2) gene at the
short arm of chromosome 9, brought new insight into
thromboembolic events. JAK2 encodes a cytoplasmic
tyrosine kinase of growth factors and cytokines like
erythropoietin, thrombopoietin, granulocyte-macrophage* Correspondence: etatar@hotmail.com
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reproduction in any medium, provided the orcolony-stimulating factor (GM-CSF) and interleukin-3
(IL-3) and functions as a co-factor for cytokine responses
in vivo and in cytokine mediated transduction pathways
leading to cell proliferation. A recent single point
mutation substituting phenylalanine for valine (V617F)
of JAK2 has resulted with dysregulation of kinase
activity and consequent overactive hematopoesis [5,6].
Indeed, JAK2 V617F mutation frequently accompanied
to chronic myeloproliferative disorders as polycythemia
vera (PV) and essential thrombophilia (ET) in recent
reports. Furthermore; patients with JAK2 V617F muta-
tion have demonstrated recurrent episodes of venous
thrombosis [5,7,8].
Splanchnic vein thrombosis (SVT) comprises extrahe-
patic portal vein, mesenteric vein and splenic vein
thrombosis either alone or together and myeloprolifera-
tive diseases (MPD) are the most common etiologic fac-
tors [9]. Besides, JAK2 mutation has been accounted for
the development of SVT, even in the absence of overt
MPD [10]. Recent studies suggested JAK2 V617F muta-
tion as a risk factor in the pathogenesis of SVT ind. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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prothrombic risk factor in renal transplant recipients is
yet to be defined.
Herein; we present a case of portosplenic vein throm-
bosis in a primary renal transplant recipient with JAK2
V617F mutation.
Case presentation
A 59 year old female ESRD patient with unknown eti-
ology,underwent a preemptive living donor kidney trans-
plant from her son on the 6th April 2011. The donor
and recipient B and T-cell crossmatch was negative. She
has been followed at the Nephrology Unit of our institu-
tion since August 2006. She received induction immuno-
suppression with rabbit anti-human thymocyte globulin
(ATG-Fresenius, 3-5 mg/kg/day) with prednisolone and
mycophenolic acid, until serum creatinine (SCr) values
reduced to 2.0 mg/dL. She had excellent initial function
with a SCr:0.94 mg/dL at the 3rd day. Post-engraftment
biopsy specimen demonstrated normal morphology of
glomeruli and vascular structures with moderate (25-50%)
acute tubular necrosis (Figure 1A). The maintenance im-
munosuppression consisted of prednisolon 30 mg/day and
mycophenolic acid 900 mg/day. A calcineurin inhibitor or
a proliferation signal inhibitor (PSI) drug was not adminis-
tered within the first week of transplantation due to pro-
found immunosuppression of ATG, being reflected by
very low CD3 +T-cell count. Post-transplant recovery was
complicated by acute graft dysfunction at day 7. Kidney
biopsy revealed de novo thrombotic microangiopathy
(TMA) with characteristic fibrin thrombi within the glom-
erular capillaries and arterioles and endothelial swelling.
There was no interstitial infiltration but features of recov-
ering acute tubular necrosis. Immunoflourescence staining
showed intracapillary fibrin thrombi in the glomeruli. C4dFigure 1 A: Post-engraftment biopsy (moderate acute tubular injury w
microangiopathy, acute tubular necrosis (HE, ×200).deposition in peritubular capillaries (PTCs) was not
present (Figure 1B). Hematological parameters, peripheral
blood smear and coagulation tests were normal with no
noteworthy changes within the last few days.
The patient was treated with pulse methylprednisolone,
Double-filtration plasmapheresis (every other day for three
times) and administration of intravenous immunoglobulins
(total dose:2 mg/kg). She had completely recovered in two
weeks with good graft function (SCr:1.0 mg/dL and eGFR
via MDRD4: 61 mL/min/1.73 m2.) and discharged from the
hospital with a maintenance immunosuppression including
prednisolone 10 mg/day, mycophenolic acid 900 mg/day
and everolimus 0.5 mg/day. Her routine follow-up was nor-
mal until the outpatient visit at 20 months after transplant-
ation. She admitted with vague abdominal pain principally
located at left upper quadrant. Abdominal ultrasound with
color-doppler imaging demonstrated splenomegaly with
hyperechoic trombi almost completely occluding splenic
vein and portal vein upto portal hilum. The spleen was
150 mm. in longitudinal axis and there were multiple areas
of nonvascularized segments both in liver and spleen.
Intraabdominal ascites and deep vein thrombosis in lower
limbs or in other abdominal organs were not present.
These findings were confirmed by abdominal magnetic res-
onance imaging angiography.
She had no history of prior venous thromboembolism or
identifiable thrombophilia. Liver and kidney function tests
were completely normal and quantitative HCV-RNA with
CMV, HBV and BK virus DNA PCR testing were negative.
The only abnormal finding was increased platelet count
(500–650 × 103/mm3) in two consecutive measurements
preceding the SVT. There was no evidence of portal hyper-
tension or esophageal varices in upper gastroduodenal en-
doscopy. The laboratory assessement, prothrombic risk
factors and clotting parameters are shown in Table 1.ith otherwise normal architecture) (HE, ×200). B: Thrombotic
Table 1 Laboratory data, genetic screening and bone
marrow analysis
Value Reference range
WBC count, ×103/mm3 6.4
Hgb level, g/L. 13.2
Haematocrit, % 42.1
Platelet count, ×103/mm3 630






Thrombophilia parameters (%) (%)
Antithrombin III (AT III) 115.5 75-125
Protein C (PC) 98.4 70-140
Protein S (PS) 87.2 60-130
Activated PC resistance (APCR) 0.36 0.69-1.56
(sec.)
Lupus anticoagulant (LA) 45.1 31-34
Lupus anticoagulant confirmation 36.5 30-38
Genetic screening (pos./neg.) Comment
Factor V Leiden mutation Positive Heterozygot carrier
BCR-ABL Mutation Negative
prothrombin G20210A mutation Negative
JAK2 V617F mutation Positive
Bone marrow biopsy YES/NO
Increased cellularity Yes (60%)
Dyserythropoesis No
Dysgranulopoesis No
Megakaryocyte abnormality Yes Dysplastic changes
Clustering of megakaryocytes Yes Paratrabecular localization
Haemophagocytosis No
Fibrosis No
Figure 2 A: MR imaging of portal vein thrombosis before anticoagula
warfarin treatment.
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sential thrombocytosis, ET) with JAK2 V617F mutation.
She was initially treated with enoxaparin 60 mg/0.6 mL.
b.i.d for three days. She received enoxaparin with war-
farin 2.5 mg/day for the following two days and switched
to warfarin (≥5 mg/day) afterwards to achieve target
INR values of 1.9-2.5. After 3 months of treatment, con-
trol MRI angiography and Doppler USG demonstrated
partial (>%50) resolution of thrombosis with recanaliza-
tion of hepatopedal venous flow. (Figure 2A and B).
There was no bleeding complication and the patient is
still on the same treatment protocol.
Discussion
The incidence of venous thromboembolism in renal trans-
plant recipients, ranges between 0.6%-25% in the literature
[2,4,12]. Many risk factors have been implicated in recur-
rent venous thrombosis or allograft thrombosis after renal
transplantation. Among them; the presence of CMV infec-
tion and cyclosporine or rapamycine administration after
transplantation are basically observations and the mechan-
ism of thrombogenicity about these drugs and infection are
not fully demonstrated in high-powered clinical trials
[13-15]. In addition; pretransplant hypercoagulable states as
vascular access thromboses, prior venous thromboembol-
ism, essential thrombocytemia, ischemic heart disease on
antiplatelet therapy, atrial fibrillation on vitamin K antagon-
ist therapy, factor V Leiden and prothrombin G20210A
mutation and the presence of antiphospholipid antibodies
have all been defined as independant risk factors for renal
allograft thrombosis but not for posttransplant SVT in pa-
tients with optimal graft function [13,16,17]. The impact of
JAK2V617F mutation in the pathogenesis of splanchnic
vein and peripheral venous thrombosis and thromboses in
MPD has been disclosed in detail [5,7,8,18-20]. A very in-
teresting finding in patients with thrombotic complica-
tions was the high prevalence of this mutation in femalent treatment. B: MRI of partial resolution of PV thrombus after
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ity, while it was uncommon in patients with venous
thrombosis at other locations or with arterial thrombosis
[18,19]. There is strong clinical evidence that JAK2V617F
mutation mediates overactivation of platelets in MPD
[21,22]. In one retrospective study including 241 cases of
SVT, the JAK2V617F mutation was identified in 34% of
MPD patients with portal vein thrombosis (PVT). Here,
the investigators suggestted JAK2V617F mutation analysis
as an initial test which should replace bone marrow inves-
tigations for MPD in patients with SVT [20]. In another
series of 99 adult patients with SVT but without an overt
MPD, 15% presented JAK2V617F mutation [23]. This
finding was reproduced and substantiated in another study
group in which this somatic mutation was present in
100% of patients with SVT and overt MPD and 41% of pa-
tients with SVT and latent MPD. Interestingly none of the
patients with latent MPD have progressed to overt MPD
more than 7 years of follow-up [24]. The frequent co-
existence of MPD, SVT and JAK2V617F mutation has di-
rected us towards genetic analysis in our patient. The
differential diagnosis of SVT late after transplantation in a
recipient with normal graft function requires exclusion of
the aforementioned risk factors or conditions that fre-
quently contribute to venous thrombosis in common or
uncommon locations. As shown in Table 1, this strategy
is used in the present case. Factor V Leiden (G1691A)
mutation was reported as a predisposing factor for throm-
botic complications in renal transplant recipients. Genetic
screening for protein C or S deficiency, antiphospholipid
and anticardiolipin antibodies and G20210A prothrombin
mutation were negative and JAK2V617F mutation was not
studied in these patients [25].
The evaluation of etiology for SVT revealed JAK2V617F
mutation accompanied by splenomegaly, thrombocytosis
and bone marrow findings (megakaryocyte cellularity and
clustering, presence of paratrabecular and dysplastic mega-
karyocytes without fibrosis) which indicates MPD, particu-
larly essential thrombocytosis. The length of secondary
prophylaxis after deep vein thrombosis (DVT) either by
standard oral anticoagulation or by low molecular weight
heparin is a matter of debate. In one study; 22 (46.8%) out
of 47 patients with DVT experienced a recurrence after the
withdrawal of antithrombotic treatment [2]. This high risk
of recurrence in renal transplant patients should alert phy-
sicians for the administration of prolonged, probably life-
long treatment, particularly to those with proven genetic
susceptibility.
Conclusion
To the best of our knowledge, this is the first case in the
literature addressing the association between JAK2V617F
mutation with MPD manifested by splanchnic vein throm-
bosis in a kidney transplant patient. This genetic studyshould be considered in kidney transplant patients with
thrombosis in uncommon sites.
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